KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 3,975 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 3,975 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $15.77 on Wednesday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The stock’s 50 day moving average is $15.47 and its two-hundred day moving average is $13.94. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.00. The firm has a market capitalization of $797.17 million, a PE ratio of -3.99 and a beta of -0.19.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Analyst upgrades and higher price targets — Multiple analysts have raised targets and reiterated buy ratings (HC Wainwright to $37, Needham to $32, TD Cowen buy), leaving a consensus target (~$29.40) well above the current price; this analyst optimism supports upside expectations. MarketBeat Analyst Coverage
• Positive Sentiment: Institutional buying — Recent 4Q moves show large new or increased stakes (Vestal Point, Invesco, Squadron Capital among buyers), signalling conviction from professional investors that may underpin the rally. MarketBeat Institutional Activity
• Neutral Sentiment: Speculative price-target article — A Zacks piece highlights a consensus-implied ~117% upside, but frames that as speculative and dependent on future earnings revisions; useful for sentiment but not a catalyst by itself. Zacks Upside Analysis
• Negative Sentiment: Insider selling by multiple executives — CEO Benjamin Palleiko sold 10,034 shares (~2.2% of his stake); CFO Brian Piekos, Nicole Sweeny and Paul Audhya also sold shares on Feb. 23. Concentrated insider sales can be viewed negatively by investors even if for diversification or tax reasons. InsiderTrades: Insider Sales

Analyst Ratings Changes

KALV has been the subject of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Needham & Company LLC upped their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KALV. Emerald Advisers LLC grew its position in shares of KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after purchasing an additional 313,205 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of KalVista Pharmaceuticals by 26.4% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock worth $8,693,000 after purchasing an additional 160,759 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $1,130,000 after buying an additional 78,450 shares in the last quarter. F m Investments LLC grew its holdings in KalVista Pharmaceuticals by 263.8% during the 2nd quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock valued at $2,060,000 after buying an additional 132,165 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in KalVista Pharmaceuticals by 391.9% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after buying an additional 160,128 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.